Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

Roche announces positive phase III results for Gazyva/Gazyvaro in primary membranous nephropathy, marking a significant milestone in this autoimmune disease

Basel, 16 February 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the phase III MAJESTY study in adults with primary membranous nephropathy met its primary endpoint, showing statistically significant and clinically meaningful results with Gazy…

  • MAJESTY, the first global phase III study in primary membranous nephropathy, met its primary endpoint of complete remission at two years
  • Up to 30% of people with membranous nephropat… [+8747 chars]

Related Posts

About FHMnews

What is FHMnews?

FHMnews is the result of a rebellion that transcended frustration. Look around you. As PK puts it, the people in this circle think one thing, say another, and do another. We shook up all three, confined within one circle, and decided to write as they think and speak. News, views, and everything beyond.

FHMnews is the country's first "new age" English news website. It's modern in its language, attitude, and news standards. It features selected news stories from the day, but with 360-degree coverage. It offers a complete report and analysis of each story, along with additional features like quizzes, polls, memes, and videos.

FHMnews Ltd.

E-43, Phase 8
Sahibzada Ajit Singh Nagar,
Punjab, 160071

Get In Touch With Us

© Copyright FHMnews